Author:
Huang Gaozhen,Xiong Hong,Li Shihao,Zhu Yi,Liu Hongwei
Funder
Natural Science Foundation of Guangdong Province
Zhanjiang Science and Technology Plan Project
Research Project of Traditional Chinese Medicine Bureau of Guangdong Province
Research Foundation for Advanced Talents of Affiliated Hospital of Guangdong Medical University
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference33 articles.
1. Administration NMPA. January 18, 2021 Drug approval document pending receipt information release [EB/OL]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210118091934189.html. 18 Jan 2021/1 May 2023.
2. Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102–2114
3. Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines® insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw 20(8):866–878
4. Galsky MD, Arija JÁA, Bamias A et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395(10236):1547–1557
5. Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103